KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Revenue (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Revenue for 16 consecutive years, with $784000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue rose 43.33% year-over-year to $784000.0, compared with a TTM value of $2.8 million through Sep 2025, up 75.19%, and an annual FY2024 reading of $1.8 million, up 35.25% over the prior year.
  • Revenue was $784000.0 for Q3 2025 at TherapeuticsMD, down from $952000.0 in the prior quarter.
  • Across five years, Revenue topped out at $68.6 million in Q4 2022 and bottomed at -$65.7 million in Q4 2021.
  • Average Revenue over 5 years is $4.1 million, with a median of $502000.0 recorded in 2023.
  • The sharpest move saw Revenue crashed 391.0% in 2021, then skyrocketed 932.08% in 2024.
  • Year by year, Revenue stood at -$65.7 million in 2021, then skyrocketed by 204.36% to $68.6 million in 2022, then crashed by 99.27% to $502000.0 in 2023, then surged by 32.87% to $667000.0 in 2024, then rose by 17.54% to $784000.0 in 2025.
  • Business Quant data shows Revenue for TXMD at $784000.0 in Q3 2025, $952000.0 in Q2 2025, and $393000.0 in Q1 2025.